An interventional study of JenaValve Trilogy Heart Valve System in Aortic Regurgitation, Aortic Valve Insufficiency and Aortic Insufficiency, sponsored by JenaValve Technology, Inc.. Active, not recruiting at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-13.
Sponsored by JenaValve Technology, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Aortic Valve Insufficiency with a site in United States — 7 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · United States.
Among the 41 studies in Aortic Valve Insufficiency with a site in United States, this one is the 17th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2020, is one of 22 with no phase, reaches primary completion later than 1 of the 16 other live ones, and was the 27th registered.
171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.
Browse Aortic Valve Insufficiency studies →7 of the 41 studies in Aortic Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18+
JenaValve Technology, Inc. · Sites in United States
The Cleveland Clinic · Sites in United States
Ages 18–90
Edwards Lifesciences · Sites in United States, Canada
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 4 started in 2020.
This study's enrollment of 180 is above the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.
Median enrollment 226 across the 24 interventional studies, 200 across the 17 observational. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 41 have an industry lead sponsor. The 10 most frequent:
JenaValve Technology, Inc. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
JenaValve Technology, Inc. has 6 studies filed under Aortic Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Aortic Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06608823JenaValve Technology, Inc.ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | 2027-06 |
| NCT04149600Beth Israel Deaconess Medical CenterIdentification of Genetic Causes of Calcific Aortic Valve Disease | 2027-06-30 |
| NCT05459233Institut universitaire de cardiologie et de pneumologie de Québec, University LavalValve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR | 2027-09-01 |
| NCT07197736Columbia UniversityDELINEATE-Prospective | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Aortic Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.
This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. In this study, TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat symptomatic severe aortic regurgitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAVR with JenaValve Trilogy Heart Valve System Intervention Device: JenaValve Trilogy Heart Valve System
Device: JenaValve Trilogy Heart Valve System
TAVR with JenaValve Trilogy Heart Valve System
All-Cause Mortality at 1 Year
All-cause mortality within the first 12 months post index procedure
Time frame: 1 year
All Stroke
Number of patients that had a stroke
Time frame: 30 days
Major Bleeding
Number of patients that had any of these events
Time frame: 30 days
Acute Kidney Injury
Number of patients that had these events
Time frame: 30 days
Major Vascular Complications
Number of patients that had these events
Time frame: 30 days
Surgery/intervention related to the device
Number of patients that had these events
Time frame: 30 days
Permanent pacemaker implantation
Number of patients that had these events
Time frame: 30 days
Total aortic regurgitation
Number of patients that had these events
Time frame: 30 days
KCCQ
KCCQ Improvement
Time frame: 1 year
Plan to share: No
Started May 2020 (actual). Primary completion is estimated for Aug 2023, 39 months after the start.
Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's planned 39 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JenaValve Technology, Inc.